Results 41 to 50 of about 2,560 (200)

Pain Associated With Head and Neck Cancer Photoimmunotherapy. [PDF]

open access: yesIn Vivo
Head and neck photoimmunotherapy (HN-PIT) achieves local control in unresectable locally advanced or recurrent head and neck cancer; however, acute post-treatment pain remains clinically important. This retrospective study evaluated pain timing and intensity, the association between a revised analgesic protocol and pain, the relationship between tumor ...
Yoshida S   +3 more
europepmc   +3 more sources

Extracorporeal photoimmunotherapy-photopheresis

open access: yesFrontiers in Bioscience, 2009
Extracorporeal photoimmunotherapy-photopheresis (ECP) is an immunomodulatory therapy, which basically consists of separating the patient's leucocyte rich plasma from the red blood cell fraction, followed by extracorporeal administration of a photosensitizer and UVA light prior to reinfusion of the treated cells.
Theresa, Dani, Robert, Knobler
openaire   +2 more sources

Biomaterial-assisted photoimmunotherapy for cancer

open access: yesBiomaterials Science, 2020
The biomaterials have been well designed as photoabsorbing/sensitizing agents or effective carriers to enhance the photoimmunotherapeutic efficacy and evade their side effects.
Muchao Chen, Qian Chen
openaire   +3 more sources

Insight into the Prospects for Tumor Therapy Based on Photodynamic Immunotherapy

open access: yesPharmaceuticals, 2022
Malignancy is one of the common diseases with high mortality worldwide and the most important obstacle to improving the overall life expectancy of the population in the 21st century.
Xiaoxia Cheng   +7 more
doaj   +1 more source

Receptor-Mediated DNA-Targeted Photoimmunotherapy [PDF]

open access: yesCancer Research, 2006
Abstract We show the efficacy of a therapeutic strategy that combines the potency of a DNA-binding photosensitizer, UVASens, with the tumor-targeting potential of receptor-mediated endocytosis. The photosensitizer is an iodinated bibenzimidazole, which, when bound in the minor groove of DNA and excited by UVA irradiation, induces ...
Tom C, Karagiannis   +4 more
openaire   +2 more sources

Additional file 1 of Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy

open access: yes, 2022
Additional file 1: Figure S1. (a) The standard curve of R837 was detected by HPLC; (b) The standard curve of ICG was measured by ultraviolet spectrophotometer; (c) Analysis of drug loading efficiency using nanometer delivery platform. Figure S2.
Gang Liu (11877539)   +10 more
core   +1 more source

Current Challenges and Opportunities of Photodynamic Therapy against Cancer

open access: yesPharmaceutics, 2023
BACKGROUND: Photodynamic therapy (PDT) is an established, minimally invasive treatment for specific types of cancer. During PDT, reactive oxygen species (ROS) are generated that ultimately induce cell death and disruption of the tumor area. Moreover, PDT
Ruben V. Huis in ‘t Veld   +5 more
doaj   +1 more source

Near‐infrared photoimmunotherapy through bone [PDF]

open access: yesCancer Science, 2019
AbstractNear‐infrared photoimmunotherapy (NIR‐PIT) is a molecularly targeted cancer phototherapy that is based on injecting a conjugate of a silicon‐phthalocyanine derivative, IRdye 700DX (IR700), and a monoclonal antibody that targets an expressed antigen on the cancer cell surface.
Yu A. Nakamura   +9 more
openaire   +2 more sources

NEAR-INFRARED PHOTOIMMUNOTHERAPY TARGETING OF CANCER-ASSOCIATED FIBROBLASTS

open access: yes, 2023
Cancer-associated fibroblasts (CAFs) constitute a prominent cellular component of the tumor stroma, representing a heterogeneous group of activated fibroblasts.
Glabman, Raisa A
core   +1 more source

Mace‐Like Plasmonic Au‐Pd Heterostructures Boost Near‐Infrared Photoimmunotherapy

open access: yesAdvanced Science, 2023
Photoimmunotherapy, with spatiotemporal precision and noninvasive property, has provided a novel targeted therapeutic strategy for highly malignant triple‐negative breast cancer (TNBC).
Yanlin Feng   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy